Inhibition of the PCR by genomic DNA
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0284538 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Sue Latham und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine and Public Health, Flinders University, Adelaide, Australia. Hauptthemen laut MEDLINE: Nucleic Acid Amplification Techniques, DNA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Monoquant Pty Ltd, Flinders University.
Abstract (Originalsprache)
Aims qPCR, is widely used for quantifying minimal residual disease (MRD) and is conventionally performed according to guidelines proposed by the EuroMRD consortium. However it often fails when quantifying MRD levels below 10 −4 . By contrast, HAT-PCR, a recent modification designed to minimise false-positive results, can quantify MRD down to 10 −6 .
Methods
The factors leading to failure of conventional qPCR to quantify low levels of MRD were studied by analysing PCR reagents, protocol and primers and by testing for inhibition by adding primers to a plasmid amplification system. Complementary primers, ending in either G/C or A/T, were used to determine the effect of the 3’ end of a primer.
Results
Inhibition of conventional PCR resulted from interaction of primers with genomic DNA leading to exponential amplification of nonspecific amplicons. It was observed with approximately half of the EuroMRD J primers tested. Inhibition by a primer was significantly related to primer Tm and G/C content and was absent when extension at the 3’ end was blocked. Nonspecificity and inhibition were decreased or abolished by increasing the annealing temperature and inhibition was decreased by increasing the concentration of polymerase. Primers terminating with G/C produced significantly more nonspecificity and inhibition than primers terminating with A/T. HAT-PCR produced minimal nonspecificity and no inhibition.
Conclusions
Inhibition of the PCR may result from the presence of genomic DNA and resultant exponential amplification of nonspecific amplicons. Factors contributing to the phenomenon include suboptimal annealing temperature, suboptimal primer design, and suboptimal polymerase concentration. Optimisation of these factors, as in HAT-PCR, enables sensitive quantification of MRD. PCR assays are increasingly used for sensitive detection of other rare targets against a background of genomic DNA and such assays may benefit from similar improvement in PCR design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Medicine and Public Health, Flinders University, Adelaide, Australia.
ORCID-Profile: Alexander Morley
Förderung
- Monoquant Pty Ltd
- Flinders University
Zitieren
APA
Latham, S., Hughes, E., Budgen, B., & Morley, A. (2023). Inhibition of the PCR by genomic DNA. PLOS ONE. https://doi.org/10.1371/journal.pone.0284538
Vancouver
Latham S, Hughes E, Budgen B, Morley A. Inhibition of the PCR by genomic DNA. PLOS ONE. 2023. doi:10.1371/journal.pone.0284538
BibTeX
@article{Latham2023,
author = {Latham, Sue and Hughes, Elizabeth and Budgen, Bradley and Morley, Alexander},
title = {Inhibition of the PCR by genomic DNA},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0284538}
}
EUVIMED